ATH alterity therapeutics limited

huntington's recruitment complete, page-2

  1. 3,120 Posts.
    lightbulb Created with Sketch. 31
    This in particular was very relevant moving forward imho:-

    "Professor Ira Shoulson, Professor of Neurology, Pharmacology and Human Science at Georgetown University (Washington DC) and the Chair of the Executive Committee of the Huntington Study Group said “PBT2 attracted our attention as an experimental drug with the potential to bring real benefit to Huntington Disease patients who suffer from a range of motor, behavioural and cognitive symptoms. The favourable signals from the PBT2 trial in Alzheimer’s Disease are particularly promising”.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
1.1¢
Change
-0.001(8.33%)
Mkt cap ! $100.4M
Open High Low Value Volume
1.2¢ 1.2¢ 1.1¢ $84.30K 7.324M

Buyers (Bids)

No. Vol. Price($)
23 28529451 1.1¢
 

Sellers (Offers)

Price($) Vol. No.
1.2¢ 1166855 4
View Market Depth
Last trade - 16.10pm 16/07/2025 (20 minute delay) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.